KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $447.0 million.

  • Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) rose 5817.94% to $447.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.0 million, marking a year-over-year increase of 5817.94%. This contributed to the annual value of $274.2 million for FY2024, which is 3192.31% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $447.0 million, which was up 5817.94% from $417.4 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $447.0 million during Q3 2025, with a 5-year trough of $23.0 million in Q1 2021.
  • Over the past 5 years, Recursion Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $201.4 million (recorded in 2023), while the average stood at $224.4 million.
  • In the last 5 years, Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) skyrocketed by 67245.54% in 2021 and then surged by 290.89% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $125.3 million in 2021, then surged by 40.04% to $175.5 million in 2022, then grew by 18.41% to $207.9 million in 2023, then skyrocketed by 31.92% to $274.2 million in 2024, then soared by 63.01% to $447.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $447.0 million in Q3 2025, compared to $417.4 million in Q2 2025 and $402.8 million in Q1 2025.